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I am delighted to welcome this excellent report from the National Advisory Committee on Drugs
(NACD) on the estimated prevalence of opiate misuse in Ireland.
The NACD was set up to address gaps in our knowledge of drug misuse in an Irish context. The
results of their three-year work programme will significantly increase the amount of available
research, which will, in turn, facilitate greater evidence-based policy-making in this difficult and
complex area. 
This latest report from the NACD, which estimates the number of opiate misusers in Ireland is a
valuable update on the 1998 Comiskey report which was based on data for Dublin only. The latest
report gives us data for Ireland, for Dublin and for the rest of Ireland excluding Dublin. 
Although there are some encouraging signs in the report, I would like to reiterate the need to avoid
any complacency. Drug misuse remains one of the major social problems facing Irish society today
and the Government will continue to work in partnership with communities most affected by the
problem. Implementing the 100 actions in the National Drug Strategy 2001 – 2008 and initiatives
such as the Local and Regional Drugs Task Forces remain a priority for Government.
This study is one of a series that the NACD is carrying out that will ultimately lead to a more
complete and reliable picture of the extent of drug misuse in Ireland. This study is a vital
component of that work and I have no doubt that it will prove very important in framing 
future drugs policy in Ireland. 
Noel Ahern T.D.
Minister of State with responsibility for the National Drug Strategy
Foreword – Minister of State
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One of the core tasks for the NACD is to advise the Government about the prevalence of problem
drug taking in Ireland. Early work by the NACD soon led to the realisation that much of the data
needed to produce an informed assessment of the extent of problem drug taking in this country, 
was not easily accessible. The NACD also came to recognise that when figures were available we
lacked the means to convert those figures into a reliable, overall determination of the numbers 
using particular drugs. While many internationally validated methods of estimating drug use were
available to us through the work of the European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA), the NACD has had to commission a range of studies to provide robust Irish data that 
can be readily incorporated into the EMCDDA’s harmonized five key indicators of problem drug use.
One of the key methodologies involves the use of the Capture-Recapture Method. The use of the 
word ‘capture’ which betrays the origins of the method in ecological studies, has unfortunate
connotations in the context of trying to estimate the number of Irish people unfortunate 
enough to develop problems involving the use of opiates (mainly heroin). However, it is one 
of the internationally recognized methods of estimating prevalence of drug use and the concept 
of ‘capture’ in this context refers to the likelihood of an individual appearing in more than one data
source. Developing reliable data sources alone has posed an enormous challenge to the researchers
and all of those in hospitals, the treatment services and An Garda Síochána who have liaised with
them. The present report, while representing a huge amount of painstaking work by Dr. Alan Kelly
and his team, is but one (albeit huge) part of a jigsaw puzzle. The NACD hopes that this report,
which covers all of the country, will provide everyone involved in responding to problem drug taking
with invaluable reliable and objective information. The figures herein need to be incorporated with
those on treatment demand from the National Drug Treatment Reporting System, with information
from the NACD’s forthcoming General Population Survey and the Network Analysis Study in order 
to fully comprehend the prevalence of drug use both nationally, regionally and locally.
The true value of all of these prevalence studies lies partly in the fact that they are grounded in
standardized internationally recognized methodologies but mainly in their provision of benchmark
figures which, when these studies are repeated at regular intervals, will allow analysis of trends 
in drug taking. The importance of being able to repeat these studies cannot be overestimated and 
in anticipation of that the NACD wishes to express its deep appreciation of the indispensable efforts
of the Commissioner and members of An Garda Síochána. We also wish to acknowledge the efforts
of the HIPE coordinators in all of the acute hospitals. We hope that the spirit of cooperation which
has been created through this pivotal study will continue into the future.
Finally, on behalf of the NACD, I would like to thank Dr. Alan Kelly and his colleagues Marlen Carvalho
and Conor Teljeur for their exhaustive and I have no doubt exhausting efforts to provide all of us
with reliable, valid, robust information on the extent of opiate use in this country. 
Dr. Desmond Corrigan
Chairperson
NACD
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and Related Criminal Activity. We would also wish to acknowledge the assistance of Dr. Joe Barry in
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The tables below provide a concise summary of the findings of this study. They show the estimated
prevalence of opiate use as numbers of individuals (males & females combined), and the
corresponding rate per 1,000 population, for the years 2000 and 2001 for:
i) Ireland as a whole;
ii) Dublin; and
iii) the rest of Ireland excluding Dublin.
Ireland
Year Age Estimated Rate/1000
group Number population
2000 15-64 14,158 5.6
2001 15-64 14,452 5.6
Dublin
Year Age Estimated Rate/1000
group Number population
2000 15-64 12,268 15.9
2001 15-64 12,456 15.9
Rest of Ireland (excluding Dublin)
Year Age Estimated Rate/1000
group Number population
2000 15-64 2,526 1.4
2001 15-64 2,225 1.2
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Summary
The data in this publication provide a revision of the figures published in May 2003 in light of the final census figures as reported in
“Population and Migration Estimates April 2002, CSO ‘Bulletin’, 5 September 2002”.
This is a report of the findings of a national 3-source capture-recapture study on the prevalence 
of opiate drug use in the population during the period 2000 to 2001. The Capture-Recapture
Methodology (CRM) is the principal indirect method for estimating the prevalence of some partially
hidden population such as opiate users. Clearly, given the nature of this population, a simple head-
count is not feasible, as many opiate users have no contact with any service provider – hence the
need to rely on a statistical model based on what we do know about this population. 
While originally developed to estimate the numbers in various wildlife populations, for example, 
a given bird species, CRM has gained in popularity as a useful tool to provide statistically valid
estimates in a wide variety of epidemiological studies. For example, CRM has been extensively used
in similar population-based opiate prevalence studies, both abroad and in Ireland in the mid-1990s,
and is the methodology recommended for this purpose by the EMCDDA, Lisbon.
The study was commissioned by the NACD following an open tendering process. This report updates
a similar (though Dublin-only) study for the year 1996.1 As such, this is the first study to provide
national figures for Ireland as a whole and for certain regions.
The research began in mid-2002 and took more than a year to complete due in large measure 
to the need to acquire certain confidential data from a number of sources. This latter requirement
necessitated that permission to hold such information on computer for the duration of the study
had to be obtained from the Data Protection Commissioner and additionally, ethical approval 
was sought and obtained from various agencies as described below.
It is anticipated that the results presented here will inform national and regional planning for
service provision by the relevant authorities. 
Background
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1 Comiskey, C. (1998) Estimating the prevalence of Opiate Drug Use in Dublin, Ireland. A Report submitted to the Department of
Health & Children, Dublin.
The main parameters of the study, as determined by the NACD Prevalence Sub-committee, specified
that three data sources were to be employed in the study, namely:
i) the Central Drug Treatment List;
ii) the national Garda Study on Drugs, Crime and Related Criminal Activity; and
iii) the Hospital In-patient Enquiry (HIPE) database.
Using these sources, statistically valid estimates of the prevalence of opiate drug use in the 
national population and by sub-region were required for the years 2000 and 2001. 
In view of the sensitive nature of the data to be employed in the study, prior ethical approval 
was considered essential. A submission was made to the Ethics Committee of the Faculty of 
Public Health Medicine and also to the Data Protection Commission with suitable guarantees 
for the safeguarding and maintenance of data confidentiality in the study and in all reporting 
of findings. In due course, approval for the study was obtained from these bodies. Permission 
was then sought and granted to access the Central Drug Treatment List and the Garda data.2
In relation to the hospital data (HIPE), a large number of hospitals throughout the country
potentially held relevant data on attendances by individual patients with a history of opiate 
use. Some 44-hospital managers were written to by the NACD requesting their co-operation and
informing them that ethical approval was being sought from the relevant hospital Ethics Committee.
Subsequently, individual applications were made to each hospital Ethics Committee where such
existed, or, as in the case of the smaller county hospitals, to a central Ethics Committee serving
several hospitals in a region. 
9
Data
2 One of us (AK) served on the Steering Committee for the Garda study.
The recommended 3-source CRM determines a prevalence estimate based on identifying individuals
who appear in one, two or all three lists of individuals within a given year. It may be helpful to
visualise this in terms of the Venn diagram below (Figure 1). Individuals found to be in common
between any pair of sources are represented in the Figure by:
T ∩ H (individuals common to both the Treatment list and HIPE list),
T ∩ G (individuals common to both the Treatment list and Garda list),
H ∩ G (individuals common to both the HIPE list and Garda list), 
and individuals found in all three lists are represented by:
T ∩ H ∩ G (individuals common to the Treatment list, the HIPE list and the Garda list). 
The remaining individuals are unique to each source, i.e. they appear only in one or other 
of the lists as: 
T (appearing only in the Treatment list), 
H (appearing only in the HIPE list) and 
G (appearing only in the Garda list). 
Figure 1: Illustration of both overlap and non-overlap of individuals common and unique, respectively, to the three
data sources.T: Treatment list; H: HIPE list; G: Garda list; T ∩ H: individuals common to both the Treatment
List and HIPE, similarly for T ∩ G and H ∩ G. T ∩ H ∩ G: individuals found in all three lists. The remaining
individuals who appear uniquely in one or other list are indicated as T, H and G.
Method
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Treatment list HIPE
Garda data
HT
G
T ∩ G
T ∩ H
H ∩ G
T ∩ H ∩ G
In all, seven numbers are needed for the statistical analysis. These are the number of individuals
common to any pair of data lists (3 numbers) and to all three data lists (1 number) and the numbers
of individuals who are unique to specific lists (3 numbers). The seven numbers are then used in 
a statistical modelling technique suited to capture-recapture modelling and known as Log-linear
Analysis. A particular model is selected (based on certain objective performance criteria) from 
the various candidate models generated, based on the 7 numbers supplied. The preferred model
provides an estimate of the total number (N) of individuals in the corresponding population of 
drug users - this is the required prevalence estimate. In view of the fact that this method supplies 
an estimate of the prevalence, a confidence interval (conventionally set to 95%) associated with 
the estimate is also required. This confidence interval provides a range of values within which - 
with a high degree of assurance - we believe the true prevalence value will lie.
Crucial to the success of the modelling exercise is the correct ascertainment of the 7 numbers
referred to above. Determining these numbers is by no means a trivial matter. In order to
accomplish this, it is important to have a reasonably unambiguous person identifier in the three
data sets. In principle, it is believed that a person’s initials, sex and full date of birth suffices to
provide a reliable match. In practice, it must be recognised that data recording practices can and 
do give rise to errors in entering any or all of these details in routinely collected data intended 
for administrative purposes. Consequently, it was necessary to develop a specific algorithm to
accomplish the required matching in a reliable manner.
The Venn diagram below (Figure 2) illustrates the distribution of numbers observed for the 15-643 age
band during 2001 in terms of the overlap as well as the unique cases for the three sources. Please
note that these figures are for illustrative purposes only as fitting a model to the combined 15-64
age band would result in a poorly fitting model that would be unreliable. Where numbers permit,
models were fitted to various age bands and for males and females separately, as reported below.
Figure 2: An illustrative example of what the Venn diagram would look like based on the 15-64 combined ages and for
both males and females for 2001. The size of the individual circles represents the numbers contributed from
the particular source. The table shows the corresponding figures using the notation introduced in Figure 1.
11
Count
(2001)
4,525
405
896
386
1,712
45
204
Source
T
H
G
T ∩ H
T ∩ G
H ∩ G
T ∩ H ∩ G
H
T
G
2001
3 The 15-64 age band was chosen in accordance with the report formats of the European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA).
An alternative representation might be of help in understanding the statistical problem to be
addressed by the modelling. The figure below shows the same information as in Figure 2. Here is
shown a 3-way cross-tabulation of the data in terms of numbers of persons present or absent in the
7 combinations already noted, plus the final cell corresponding to the unknown number absent (i.e.
missing) from all 3 lists. This is the number of hidden individuals we seek to determine via the model.
Treatment
Present Absent
HIPE
Present Absent Present Absent
Garda Present 204 1,712 45 1,896
Absent 386 4,525 405 missing
Figure 3: A cross-tabulation of all individuals 15-64 years of age according to their presence in one, two or three lists.
The number in the cell marked ‘missing’ is to be estimated by the model.
12
A comparative analysis of the demographic characteristics across the data sets is of particular
interest in highlighting certain similarities and especially certain differences in the age/sex
breakdown within the three sources. This analysis follows the removal of duplicate records within
individual lists. For purposes of these analyses, two years data (2000 and 2001) have been
consolidated to provide added stability in the percentages displayed.
The overall percentage of cases by each source is as follows: 
• Garda list (32.8%),
• HIPE list (9.2%), and 
• Treatment list (57.9%).
The Treatment list clearly contributes by far the largest percentage of persons, followed by the
Garda list and finally by those in HIPE.
Distribution by Age Band and Person Sex
Table 1: Percentage of persons according to age band within source
% by Source
Age band % Garda HIPE Treatment
15-24 37.4 47.1 34.5 32.5
25-34 45.6 42.2 43.8 47.7
35-64 17.0 10.7 21.7 19.8
There is evidence of a very strong statistical association (p<0.001) between age group and source
(Table 1). Note that the highest in-column percentage for the Garda source is in the 15-24 age band;
while in the HIPE and Treatment lists it is in the next age band (25-34 years). In the Garda data, the
percentages are almost equal in the first two age bands, with a sharp decline in the percentage 
in the 35-64 age band. The fall off in percentages is similar but more gradual in the HIPE and
Treatment lists with a clear preference for the 25-34 year age band. Figure 4 (below) illustrates 
the distribution of males and females (for 2001 only) by age in the combined data from all three
sources. The difference in frequencies at all ages is very evident, as is the tailing off of females 
much earlier in terms of age. The overall shape of both distributions is quite similar.
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Data – A Comparative Analysis by Source
Person Sex by Source
Irrespective of source, the proportion of females was found to be only 29% overall.4
A tabulation of the percentage of males and females by source is provided in Table 2. Again, 
there is evidence of a very strong statistical association (p<0.001) between gender and source.
Table 2: Percentage of males and females within source
Gender Garda HIPE Treatment
Female 19.1 46.2 31.8
Male 80.9 53.8 68.2
The Garda data are considerably at variance with both HIPE and the Treatment list with less than
20% females as compared with over 46% in HIPE and 32% in the Treatment list. An analysis of
gender by source, while controlling for age group, will ascertain whether this association is similar
across age bands; Table 3 explores this issue.
Figure 4: Frequency distributions by age of males and females (2001 only)
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4 This percentage represents a sample weighted average of percentages in Table 2.
5 Weighted according to percentage of males and females within each source in Table 4.
Person Sex by Source within Age Band
Table 3: Percentages by person sex within source for each of 3 age groups
Age 15-24 years Age 25-34 years Age 35-64 years
Sex G H T G H T G H T
Female 21.4 56.2 41.8 18.2 44.9 30.7 13.2 33.0 23.0
Male 78.6 43.8 61.2 81.8 55.1 69.3 86.8 67.0 77.0
Within the youngest age band, the basic pattern is similar to that outlined in Table 2 although with
an increased representation of females across the 3 sources, modest in the Garda data, but higher 
in both the HIPE and Treatment lists.
In the middle age band (the largest numerically) the percentages are quite similar to the cross-
tabulation of gender by source regardless of age. Again, the most pronounced difference is in the
Garda data with a much lower proportion of females.
In the last age band, we see a decline in the percentage of females represented in each source
when compared to the previous age bands, but this is more evident for the HIPE and Treatment lists.
A more formal statistical modelling of the relationship between age (in years), sex and source and
the interaction between sex and source, confirms that:
• on average males tend to be older than females (28 years and 26 years, respectively), and
• average age5 (rounded to the nearest whole age) is lowest in the Garda data (26 years), and
similar in HIPE (29 years) and the Treatment list (29 years).
There is a significant interaction between source and gender in relation to age as illustrated in Table
4. Males tend to be typically 1 to 2 years older, with a positive trend in increasing age across the
Garda, HIPE and Treatment lists in that order. 
Table 4: Average age for males and females by source
Sex by source Average age
Females in Garda data 25.1
Females in HIPE 27.4
Females in Treatment list 27.3
Males in Garda data 26.3
Males in HIPE 29.9
Males in Treatment list 29.3
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Source by Health Board
Table 5: Percentage of persons by Health Board within source
Health Board Garda HIPE Treatment
Eastern Regional Health Authority 91.4 92.3 96.8
All Other Health Boards 8.6 7.7 3.2
Almost all of the cases (greater than 90% of the column percentages) identified in each source were
located within the Eastern Regional Health Authority6.
16
6 The Eastern Regional Heath Authority (ERHA) consists of three Area Health Boards the Northern, East Coast and South Western
Area Health Boards.
The results are presented in the following order:
1. Ireland
2. Dublin
3. Rest of Ireland excluding Dublin
4. Dublin 2001 versus Dublin 1996
Where possible, analyses have been reported by 3 age bands: 15-24, 25-34 and 35-64 years for males
and females separately. However, the data are too sparse outside Dublin to enable this level of
detail and for the ‘Rest of Ireland’ we report the combined age group 15-64 years for males and
females. No reliable CRM estimates are possible by Health Boards due to the small numbers of
persons observed.
Please note the following abbreviations used in the tables and figures to follow:
T = Treatment list.  H = HIPE data.  G = Garda data.
Lower Bound , Upper Bound = Lower and Upper 95% confidence limits, respectively.
Consistency of Results
The reported prevalence estimates for combined age/sex totals or for individual age/sex
combinations by sub-region (i.e. Dublin or the ‘Rest of Ireland’) will not necessarily be entirely
consistent, i.e. adding estimates within age/sex bands across regions need not give the same 
figure as that reported for Ireland as a whole. There are two issues here that can contribute to 
this apparent inconsistency: one is that the estimation procedure is statistical in nature – it is 
not a simple head count, while the second relates to data completeness. 
For the first issue, it should be borne in mind that each individual estimate is derived from a specific
fitted statistical model and the latter can be sensitive to the exact combination of numbers supplied
in the 7 cells derived from the 3-sources (see Figure 1). Actually, seven differently structured models
– reflecting different dependencies between the three lists - are routinely fitted to each set of observations
in order to derive the required estimate. The quality of fit of these 7 models can vary considerably
with major differences in the proposed prevalence estimate and associated confidence interval.
Based on the reported statistical information on model fit, the most appropriate model is selected.
But in any given instance, even this model may be a relatively poor fit to a set of observations thus
reducing the reliability of the estimate for that particular age/sex/year/location. For the chosen
model, the statistical uncertainty in the estimate is reflected in the 95% confidence interval and 
this implies that the true value is believed to lie somewhere within that interval – the point
estimate is simply the ‘best guess’. 
The second issue that contributes to the problem is the inadequacies of the raw data. For instance,
17
Results
matching individuals across the 3 sources depends on the complete and proper recording of details
of initials, sex, date of birth and county of origin. There is scope for error in person details within
and between data sets (e.g. middle initial included/omitted, date recorded as month/day/year in
one data set and day/month/year in another, etc. etc.). We have developed a probability-matching
algorithm to cope with these difficulties. This will compensate to some degree for omissions or
errors but clearly some residual uncertainty remains. A particular problem can arise when county 
of origin is omitted. This causes no difficulty for the model for Ireland as a whole, but will obviously
cause problems for sub-regional models. These practical difficulties must be addressed in order 
to supply estimates by different age and sex combinations for different regions.
1) Ireland
Table 6: Summary of the results of the 3-source Capture-Recapture models for Ireland 
for the years 2000 and 2001 stratified by age and sex
Year Sex Age Estimates Lower Upper Rate/
Group Bound Bound 10007
2000 Males 15-24 3,480 3,298 3,691 10.4
25-34 3,935 3,753 4,144 13.7
35-64 2,344 2,013 2,803 3.6
Females 15-24 1,866 1,664 2,142 5.8
25-34 1,729 1,542 1,983 6.1
35-64 804 614 1,120 1.2
Total M+F 15-64 14,158 12,884 15,883 5.6
2001 Males 15-24 3,194 3,048 3,363 9.5
25-34 4,376 4,206 4,570 14.7
35-64 2,228 2,042 2,462 3.3
Females 15-24 1,999 1,750 2,340 6.2
25-34 1,941 1,765 2,178 6.6
35-64 714 594 906 1.1
Total M+F 15-64 14,452 13,405 15,819 5.6
(NB: Lower Bound = lower 95% Confidence Limit. Upper Bound = Upper 95% Confidence Limit)
18
7 Rates for this and subsequent tables are derived from Central Statistic Office (CSO) population estimates: i) “Population and
Migration Estimates April 2000, CSO ‘Bulletin’, 12 September 2000”, ii) “Population and Migration Estimates April 2002, CSO
‘Bulletin’, 5 September 2002”, iii) “Population and Migration Estimates April 2001, CSO ‘Bulletin’, 29 August 2001”.
Figure 5: Bar chart of the results for 2001 with the 95% confidence intervals shown
2) Dublin
Table 7: Summary of the results of the 3-source Capture-Recapture models for Dublin 
for the years 2000 and 2001 stratified by age and sex
Year Sex Age Estimates Lower Upper Rate/
Group Bound Bound 1000
2000 Males 15-24 3,083 2,915 3,278 32.2
25-34 3,417 3,256 3,607 34.9
35-64 1,940 1,678 2,312 10.8
Females 15-24 1,714 1,533 1,958 17.5
25-34 1,497 1,342 1,713 14.4
35-64 617 480 857 3.2
Total M+F 15-64 12,268 11,204 13,725 15.9
2001 Males 15-24 2,735 2,604 2,888 29.3
25-34 3,740 3,589 3,915 36.3
35-64 1,803 1,657 1,992 9.9
Females 15-24 1,766 1,537 2,085 18.7
25-34 1,784 1,621 2,003 16.2
35-64 628 511 828 3.2
Total M+F 15-64 12,456 11,519 13,711 15.9
(NB: Lower Bound = lower 95% Confidence Limit; Upper Bound = Upper 95% Confidence Limit) 19
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Figure 6: Bar chart of the results for 2001 with the 95% confidence intervals shown
Figure 7: Juxtaposed charts for Ireland and Dublin illustrating the essentially similar patterns 
of prevalence by age and sex20
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3) Rest of Ireland (excluding Dublin)
Table 8: Summary of the results of the 3-source Capture-Recapture models for Rest of Ireland
(excluding Dublin) for the years 2000 and 2001 stratified by sex for 15-64 years combined
Year Sex Age Estimates Lower Upper Rate/
Group Bound Bound 1000
2000 Males 15-64 1,499 1,266 1,816 1.7
Females 15-64 1,027 627 1,823 1.2
Total M+F 15-64 2,526 1,893 3,639 1.4
2001 Males 15-64 1,688 1,493 1,940 1.8
Females 15-64 537 441 685 0.6
Total M+F 15-64 2,225 1,934 2,625 1.2
(NB: Lower Bound = lower 95% Confidence Limit; Upper Bound = Upper 95% Confidence Limit)
4) Dublin 2001 contrasted to Dublin 1996
As the Comiskey study in 1996 included individuals aged 15 to 54 years of age, the estimates for
Dublin 2001 have been recomputed to facilitate comparison. These are shown in Table 9 and
illustrated in Figure 8.
Table 9: Numbers of persons identified across sources for Dublin in 1996 and 2001
Source for 1996 estimates: Comiskey, C., and Barry, J. (2000) A Capture-Recapture Study of the
prevalence and implications of opiate use in Dublin, European Journal of Public Health.
21
2001
4,215
333
1,451
369
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37
191
1996
2,125
193
3,015
160
764
121
191
Source
T
H
G
T ∩ H
T ∩ G
H ∩ G
T ∩ H ∩ G
1996
2001
Figure 8: Venn diagram representation of data for Dublin in 1996 and 2001. The size of the individual circles represents
the numbers contributed from the particular source. This figure corresponds to Table 9 above
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Table 10: Prevalence estimates, confidence intervals and corresponding rates per 
thousand population by age and sex for Dublin 1996 and 2001
Dublin 1996 Dublin 2001
Estimate Lower Upper Rate/ Estimate Lower Upper Rate/
bound bound 1000 pop. bound bound 1000 pop.
M 15-24 5,405 4,980 5,891 56 2,735 2,604 2,888 29.3
M 25-34 3,512 3,276 3,778 42 3,740 3,589 3,915 36.3
M 35-54 1,427 1,175 1,773 11 1,793 1,648 1,980 13.0
F 15-24 1,778 1,525 2,108 18 1,766 1,537 2,085 18.7
F 25-34 1,039 875 1,265 11 1,784 1,621 2,003 16.2
F 35-54 300 206 491 2 626 509 825 4.2
Total 13,461 12,037 15,306 21 12,444 11,508 13,696 18.2
(NB: Lower Bound = lower 95% Confidence Limit; Upper Bound = Upper 95% Confidence Limit)
Note that the confidence bounds for both point estimates overlap substantially and we conclude
that there is a negligible difference in the prevalence for both years. The rate has declined in 2001
versus 1996 due to the (approximately) 22% increase in the population 15-54 years over the 5-year
period. These results are illustrated in Figure 9 below.
A contrast between Dublin results for 2001 and 1996 for persons aged 15-54 years
Figure 9: Prevalence estimates (with 95% confidence intervals indicated) by age and sex for Dublin 1996 and 2001 and
totals for 15-54 years males and females combined
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Comments on the Estimates for Dublin 1996 and 2001 (Table 10 and Figure 9)
Age band: 15-24
There is evidence of a marked decrease in both the rate and in the estimated number of opiate 
users in this age band for males only. The CSO report a 6.5% decline in the population of males 
in this age band for Dublin between 1996 and 2001. For females, there is essentially no difference 
in the estimates. Given the 5-year gap in the reported estimates, many of those aged 15-24 years 
in 1996 would have aged by 5 years and would – by 2001 - be counted in the 25-34 age band. 
Age band: 25-34
The 25-34 age band shows a modest increase in prevalence for males but a significantly higher
proportionate increase for females. The rate for males has declined somewhat while that for females
has risen. The population rose by 21% and 23% for males and females, respectively, over the 5 years.
Age band: 35-54
There has been an increase in both the rate and prevalence for males in this age band. The
estimated prevalence and rate for females is seen to have more than doubled between 1996 and
2001, although this is with respect to a low base number. During the 5-year period, the population
rose by over 9% for both males and females for this age group.
Total
The final pair of bars in Figure 9 shows the estimated totals across all age bands for males and
females combined for both years. In terms of the point prevalence estimates there has been a
decline of just 1,000 opiate users (from 13,462 in 1996 to 12,444 in 2001). However, it is relevant 
to note that the 95% confidence intervals overlap (viz. 12,037 – 15,306 in 1996 and 11,508 – 13,696
in 2001) and so from a strictly statistical perspective, we lack strong evidence of a real decline in 
the numbers of opiate users in this 5-year period.
Prevalence Estimates
The 3-source CRM results for Ireland as a whole suggest a figure of 14,158 as the prevalence
estimate of opiate users (aged 15-64) for 2000 (a rate or 5.6/1000 population) with a modest rise 
to 14,452 for 2001 (a rate of 5.6/1000 population). On the available evidence, there has been little 
or no real increase in prevalence between 2000 and 2001 as the respective confidence intervals
overlap substantially, and therefore we cannot conclude that any trend exists.
The point estimates for Dublin are 12,268 for the year 2000 (15.9/1000 pop.) and 12,456 for the 
year 2001 (15.9/1000 pop.). Again, no evidence of any significant difference between both years.
The Rest of Ireland (excluding Dublin) estimates are 2,526 for the year 2000 (1.4/1000 pop.) 
and 2,225 for the year 2001 (1.2/1000 pop.). 
No 3-source CRM estimates are available on an individual Health Board basis.
In comparing the estimates for Dublin for the year 1996 with those for the year 2001, there has been
a drop of just 1,000 in the prevalence of opiate users. However, taking account of the statistical
uncertainty in these two point estimates, there is no compelling evidence of a real difference
between the two time periods.
Study Limitations
The analysis shows that contact with the three sources differs depending on the age and sex of the
person. In particular, it was found that younger females are less likely to appear in the Garda data
when compared with both the HIPE and the Treatment lists. This implies that the probability of
being ‘captured’ by the Garda data differs from that of HIPE and the Methadone Treatment list, at
least with respect to this category. This violates one of the underlying assumptions for the CRM (i.e.
the presumed equal probability of being ‘captured’ by all sources) with the result that the estimates
are possibly biased downwards.
A second relevant assumption - that the population is closed (i.e. that there is no migration in 
or out of the region) - may also be violated to some extent when considering the sub-regions and
particularly when year-on-year estimates are compared as eastward migration of opiate users may
have occurred from the regions. 
An important limiting consideration for the reliable applications of the CRM is the requirement for 
a high overlap of information across the sources. In this study, the 2 and 3-source overlap was low
or very low for certain age/sex combinations (e.g. for 3-source overlap: females in the 35-64 age
band; for 2-source overlap: HIPE with Garda data for most age/sex combinations) and where this
occurs it will give rise to a less reliable point estimate with a wide confidence interval.
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Concluding Remarks
Continuity
As this was the first national CRM exercise, a number of valuable lessons have been learned. The
acquisition of the hospitals’ data was a particularly lengthy process due to the need to contact a
large number of hospitals nation-wide and – in most instances – the requirement to make a formal
application to their ethics committees. With appropriate national ethical approval, this process
could well be semi-automated for any future CRM exercise with a considerable saving in time and
effort. As the Treatment list is maintained on an on-going basis and is therefore current, it should 
be possible to undertake a 2-source annual or bi-annual CRM for monitoring purposes. The special
survey conducted by the Garda is not likely to be repeated annually, but could be undertaken every
3 or so years to enable updating of the 3-source estimates.
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